The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.

Orum Therapeutics executives talk to Scrip on the next steps for the targeted protein degradation pioneer after a large-scale financing and on likely developments in the space in the coming years.